Table 3 Adjusted association with time to death from Landmarks post 1st stereotactic radiosurgery

From: Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)

Patient Characteristics

Hazard Ratio

95% CI

P-value

Landmark 1

Systemic PD prior to LM1 vs not.

4.28

1.98, 9.12

0.0002

Age (per decade)

0.82

0.63, 1.06

0.1264

Race (white vs not white)

0.96

0.38, 2.43

0.9257

KPS 90–100 vs <90

0.52

0.26, 1.01

0.0537

ER + /Her2- vs Her2+

2.08

1.01, 4.25

0.0456

ER-/Her2- vs Her2+

2.28

0.92, 5.60

0.0736

Brain Mets at SRS1 ( > 1 vs 1)

1.92

1.01, 3.62

0.0455

PTV (per log)

1.02

0.83, 1.26

0.8504

Fractions (1 vs 3 or 5)

1.14

0.55, 2.36

0.7206

Landmark 2

Systemic PD prior to LM2 vs not.

7.40

3.10, 17.63

<0.0001

Age (per decade)

0.87

0.66, 1.14

0.3004

Race (white vs not white)

0.56

0.21, 1.50

0.2451

KPS 90–100 vs <90

0.55

0.26, 1.18

0.1267

ER + /Her2- vs Her2+

1.23

0.57, 2.66

0.5966

ER-/Her2- vs Her2+

1.06

0.38, 2.95

0.9095

Brain Mets at SRS1 ( > 1 vs 1)

1.59

0.78, 3.25

0.2066

PTV (per log)

1.15

0.90, 1.46

0.2625

Fractions (1 vs 3 or 5)

1.22

0.54, 2.78

0.6366